Healthcare Industry News: abdominal aortic aneurysm
News Release - November 19, 2014
Cordis Corporation Leads With Strong Podium Presence At VEITH 2014 With First-Ever Presentation Of Three-Year INCRAFT(R) System DataFREMONT, Calif., Nov. 19, 2014 -- (Healthcare Sales & Marketing Network) -- Cordis Corporation announced today the presentation of new data from the most recent clinical studies at the 2014 VEITHsymposium®, showcasing the company's diverse and strong endovascular technology portfolio. One of the featured Cordis podium presentations is the first-ever presentation of the three-year INCRAFT® AAA Stent Graft System (INCRAFT® System) Innovation study data.
"Cordis has launched a number of exciting products over the last 18 months, including the S.M.A.R.T® Flex Stent, Chocolate® PTA Balloon Catheter, SABER™ PTA Dilatation Catheter, and most recently, the INCRAFT® System. These technologies are among the Cordis products to be showcased at the Cordis booth1, the Cordis Pavilion2, or in podium presentations at the 2014 VEITHsymposium®," said Celine Martin, Worldwide President, Cordis Corporation. "Cordis is committed to advancing standards of care for endovascular interventions with a prime focus on clinical research and new technology solutions."
Overview of Presentations at VEITHsymposium®
INCRAFT® AAA Stent Graft System
Cordis launched the INCRAFT® System in Europe and Canada in September 2014, representing a significant advancement in the treatment of infrarenal abdominal aortic aneurysms (AAA). The INCRAFT® System features an ultra-low profile 14F outer diameter3 delivery system to simplify access, navigation, and deployment. The customizable tri-modular design of the INCRAFT® System also offers bilateral in-situ adjustments, substantially improving placement accuracy.
Two new oral presentations at the VEITHsymposium® will add to the body of scientific evidence supporting the INCRAFT® System
- The "3-Year European Results With A Lower Profile Device for EVAR: Advantages of the INCRAFT® From Cordis: The INNOVATION Trial" will be presented by Prof. Dr. Giovanni Pratesi, University of Rome Tor Vergata, on Nov. 20 at 8:16 a.m. EST in the Grand Ballroom West. This is the first oral presentation of the three-year INNOVATION study data.
- The "US Experience With The New Cordis INCRAFT For EVAR: Advantages and Limitations" will be presented by Dr. Michel Makaroun, Co-Director of UPMC Heart and Vascular Institute and Professor and Chair of Division of Vascular Surgery, on Nov. 20 at 8:22 a.m. EST in the Grand Ballroom West.
Chocolate®PTA Balloon Catheter
In April 2014, Cordis expanded its portfolio of angioplasty solutions to advance the treatment of complex vascular disease with the launch of the Chocolate® Balloon in the U.S. Encased in a nitinol constraining structure, the Chocolate® Balloon provides uniform and predictable inflation, leading to sustained luminal gain while overcoming the significant clinical challenge of flow-limiting dissection. The Chocolate® Balloon has been used to treat above-the-knee (ATK) and below-the-knee (BTK) lesions to help avoid amputation in over 10,000 patients in the U.S. Dr. Jihad Mustapha, Director of Cardiovascular Catheterization Laboratories, Metro Health Hospital in Wyoming, MI, will present "The Chocolate® Balloon: A New Better Less Traumatic Drug Coated Balloon for Dilating Arterial Lesions With Less Dissection: Mode of Action, Advantages And Clinical Experience" on Nov. 19 at 3:42 p.m. EST in the Grand Ballroom West. Longer-term data (up to 12 months) from the Chocolate® BAR Study, with the Chocolate® Balloon, are expected to be available in 2015.
The Cordis family of S.M.A.R.T.® Stents are the world's most used, studied and clinically proven nitinol stents with well over a decade of experience. The S.M.A.R.T® Stent is designed to provide outstanding scaffolding and support to the vessel and features high radial force and longitudinal stability. The STROLL three-year outcomes presentation, "3-Year Results Of The STROLL Trial With Smart Stents In The SFA: Patency and Quality of Life Are Maintained," will be presented on Nov. 20 at 1:00 p.m. EST in the Grand Ballroom West by Michael R. Jaff, DO, Paul and Phyllis Fireman Chair of Vascular Medicine, Massachusetts General Hospital, and Professor of Medicine, Harvard Medical School, Boston, Massachusetts. The STROLL study adds to a large collection of S.M.A.R.T® Stent investigations ranging from retrospective analyses, to prospective registries and single- and double-arm randomized clinical trials.
Now in its fourth decade, VEITHsymposium® provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features over 900 rapid-fire presentations from world-renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. To register to attend the VEITHsymposium®, please visit www.VEITHpress.org or contact Pauline T. Mayer at 631.979.3780.
About Cordis Corporation
Cordis Corporation, part of the Johnson & Johnson Family of Companies, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with experts worldwide to treat millions of patients who suffer from vascular disease. More information can be found at www.cordis.com.
1 Cordis Booth is #411
2 The Cordis Pavilion ("The Cordis Experience") is located in the Hilton Hotel on the 2nd floor, Gibson Suite
3 16F outer diameter for the 34mm aortic bifurcate
Chocolate® is a trademark of TriReme Medical, LLC. All rights reserved.
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Cordis Corporation and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges inherent in new product development, including obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to laws and regulations and domestic and foreign health care reforms; and general industry conditions, including trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Cordis Corporation nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.)
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.